Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in <i>NRAS</i>-mutant cutaneous melanoma.
Reinhard Dummer(University Hospital of Zurich), Keith T. Flaherty(Cancer Research Center), Ana Arance(Hospital Clínic de Barcelona), Mario Mandalà(University of Perugia), Valentine Jehl(Novartis (Switzerland)), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Michele Maio(University of Siena), James Ford, Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Dirk Schadendorf(National Center for Tumor Diseases), Ernesto Wasserman(Merus (Netherlands)), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Viviana Bozón(Array BioPharma (United States)), Georgina V. Long(The University of Sydney), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), L. Thomas(University of Liverpool), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Marine Weill(Novartis (Switzerland)), L. Andres Sirulnik
Cited by 30
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k